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Abstract— Fontan patients often develop circulatory failure and are 
in desperate need of a therapeutic solution. A blood pump surgically 
placed in the cavopulmonary pathway can substitute the function of 
the absent sub-pulmonary ventricle by generating a mild pressure 
boost. However, there is currently no commercially available device 
designed for the cavopulmonary application; and the risks and 
benefits of implanting a ventricular assist device (VAD) originally 
designed for the left ventricular application on the right circulation 
of failing Fontan patients is not yet clear. Moreover, further 
research is needed to compare the hemodynamics between the two 
clinically-considered surgical configurations for cavopulmonary 
assist, with Full and IVC Support corresponding to the entire 
venous return or only the inferior venous return, respectively, being 
routed through the VAD.  In this study, we used a numerical model 
of the failing Fontan physiology to evaluate the Fontan 
hemodynamic response to a left VAD during the IVC and Full 
support scenarios. We observed that during Full support the VAD 
improved the cardiac output while maintaining blood pressures 
within safe ranges, and lowered the IVC pressure to <15mmHg; 
however, we found a potential risk of lung damage at higher pump 
speeds due to the excessive pulmonary pressure elevation. IVC 
support, on the other hand, did not benefit the hemodynamics in the 
patient cases simulated, resulting in the superior vena cava pressure 
increasing to an unsafe level of >20 mmHg. The findings in this study 
may be helpful to surgeons for recognizing the risks of a 
cavopulmonary VAD and developing coherent clinical strategies for 
the implementation of cavopulmonary support.   
 
Index Terms— Ventricular assist device (VAD), lumped 
parameter network model, congenital heart disease, Fontan 
I. INTRODUCTION 
ver the past 50 years, Fontan operation has been the most 
common palliative care for patients with single ventricle 
defect. Currently 50,000-70,000 patients exist worldwide 
that have been able to survive into adulthood because of the 
Fontan operation [1]. Ohuchi et al. [2] studied the 
hemodynamics in nearly 500 Fontan patients, separating them 
into early (0.5-5 years postoperative) and late (≥15 years 
postoperative) groups; the age range for the early and late 
groups were 9±6 years and 23±7 years, respectively; they 
showed that the long-term outcomes of the Fontan operation is 
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associated with high mortality. A significant number of these 
patients will eventually develop circulatory failure as a result of 
the poor hemodynamics following the Fontan procedure [3], 
[4]. Based on a 10 year follow up study, 1 out of 4 children after 
the Fontan operation are not expected to survive [4]. Previous 
clinical measurements [4]–[6]  have recorded pulmonary 
arterial hypotension and high caval pressure (also known as the 
“Fontan paradox”) in single ventricle patients after the Fontan 
procedure. Chronic high caval pressure is found to be the main 
determinant of many Fontan-related diseases and circulatory 
failure [7]. Failing stage in a Fontan circulation manifests itself 
in a cascade of the pathological consequences such as protein-
losing enteropathy, hepatic failure, and gut dysfunction [8]. 
Most failing Fontan patients are unable to receive heart 
transplantation either because they are poor candidates as a 
result of the several previous surgeries and multiple organ 
dysfunctions, or because of the unavailability of matching 
organ donors; these patients are in need of an immediate 
therapeutic solution. The use of ventricular assist device (VAD) 
for systemic circulatory support (left support) [9], [10] or 
cavopulmonary support (right support) [11]–[13] has been 
proposed for treatment of Fontan failure.  This study focuses on 
the cavopulmonary support scenario where a mechanical assist 
device propels the venous return forward into the lungs as an 
attempt to reverse the Fontan paradox.  Conceptually, a pump 
properly implemented in the cavopulmonary pathway could 
generate a slight pressure boost that benefits the hemodynamics 
by lowering the caval pressure and augmenting the cardiac 
output. Earlier studies either have suggested implementing the 
cavopulmonary device to directly pump the inferior vena cava 
(IVC) flow to the pulmonary artery (“IVC assisted 
configuration”) [13]–[16] or proposed the “Fully assisted 
configuration”  to pump the entire venous return to the 
pulmonary artery [11], [17] (Fig. 1). Previously, Molfetta et al. 
[16] showed that an ideal cavopulmonary pump could promote 
the cardiac output by 34% during IVC support. To our 
knowledge, there has been no study that directly assesses how 
the hemodynamics compare between these two surgical 
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configurations for the installation of the cavopulmonary assist 
device. 
A concerted work is in progress to develop a cavopulmonary 
assist device as a bridge to cardiac transplantation or for long-
term support. Researchers have suggested several prototypes 
for powering the Fontan circulation [14], [18]–[21].  While 
these prototypes are designed to be compatible with a low-
pressure operating environment, they are not commercially 
available and thus not employed in the clinical management of 
single ventricle patients. As such, a relevant clinical question is 
whether an existing VAD originally designed for the left side 
application can be used as right-side support in a failing Fontan 
patient. 
 Therefore, the objectives of this study are 1) to identify the 
possible risks and benefits of the off-label use of the Jarvik 2000 
(or another left VAD with similar mechanical performance) for 
IVC and Full support in adult failing Fontan patients, and 2) to 
assess how the hemodynamics compare between the IVC and 
Fully assisted surgical configurations for installation of the 
cavopulmonary assist device. We hypothesized that it is 
possible to use a left VAD for the cavopulmonary application 
and to palliate the failing Fontan condition albeit with potential 
risks. To test this hypothesis, we first performed a sensitivity 
analysis on a lumped parameter network (LPN) model of the 
healthy adult Fontan physiology to attain a quantitative 
understanding how different factors affect the Fontan 
circulation; next we constructed a failing Fontan circulation 
model and simulated the IVC and Fully assisted surgical 
configurations to determine hemodynamic aberrations of each 
configuration at different pump speeds. 
 
II. MATERIAL AND METHODS 
A. Physiology model of the healthy Fontan circulation 
(baseline) 
A closed-loop LPN was employed to model the Fontan 
physiology (Fig. 2). A full description of the modelling protocol 
has been described in our previous work [22]. Briefly, the LPN 
can adjust model parameters such as cardiac function, vascular 
resistances, vascular compliances, and respiratory parameters 
to simulate the hemodynamics of a Fontan patient. The 
transmyocardial pressure (Psv) generated by the single ventricle 
drives the flow in the circuit and is defined to be correlated with 
the ventricular elastance and volume. The ventricular time-
dependent elastance “E(t)” is defined as a function representing 
ventricular filling and contraction.   
 
𝑃௦௩ ሺ𝑉௦௩, 𝑡ሻ ൌ 𝐸ሺ𝑡ሻ ሺ𝑉௦௩ െ 𝑉௦௩௢ሻ  (1) 
𝐸ሺ𝑡ሻ ൌ  𝐸௠௔௫ 𝐸𝑛 ቀ ଴.ଷ௧ೞೡೞ 𝑡ቁ ൅  𝐸௢௙௙௦௘௧ (2) 
t is the time point in the cardiac cycle. The systolic period is 
given by tsvs, where Vsv0 and Vsv are the ventricular reference 
volume and ventricular volume, respectively.  En is the 
normalized elastance function. Emax is related to the contractility 
and ventricular ejection fraction. Eoffset reflects ventricular 
filling. The ventricular compliance is correlated with 
ventricular filling and thus Eoffset is also considered as a measure 
of the ventricular compliance. 
In this study, we tuned the LPN models according to [22] to 
represent two healthy adult example Fontan patients with a 
small and large body surface area (BSA) under resting 
condition. The small patient has weight=50kg and 
height=150cm and the large patient has weight=75kg and 
height=180cm. 
B. Sensitivity analysis 
Most of the single ventricle patients following the Fontan 
operation display signs of ventricular diastolic dysfunction and 
elevated pulmonary vascular resistance [23]–[25]. To 
determine how ventricular diastolic dysfunction and pulmonary 
vascular resistance affect hemodynamic parameters such as 
cardiac output, atrial pressure, and IVC pressure in a failing 
Fontan circulation, we performed a sensitivity analysis using 
LPN simulations where in each example patient we decreased 
the ventricular compliance by an amount from 0 to 75% and 
increased the pulmonary vascular resistance by an amount from 
0 to 100% of their baseline values with a step change of 25%. 
We maintained the ventricular contractility at its baseline value 
because previous studies have shown that ejection fraction is 
mostly preserved in the majority of failing and healthy Fontan 
patients [24], [26], [27]. 
C. Physiology model of the failing Fontan circulation  
A failing circulation is characterized by high pulmonary 
vascular resistance and low cardiac output [7]. Increased 
pulmonary vascular resistance is partly attributable to low 
pulmonary pressure and attenuated pulmonary vascular 
pulsatility in Fontan patients [25]. Clinical reports show that on 
average in a failing Fontan circulation, pulmonary vascular 
resistance is elevated by 68% [7] and cardiac output is reduced 
by 40% [7], [28] compared to the healthy Fontan circulation. 
Moreover, Hebson et al. [5]  reported that adult failing 
Fontan patients had lower systemic vascular resistance in 
comparison with asymptotic Fontan patients, possibly due to 
the autonomic control maintaining the total vascular resistance. 
A previous report showed that 73% of the Fontan patients also 
Fig. 1. Schematic representation of the surgical configurations for the 
cavopulmonary assist installation. (A) Fully assisted configuration (Full 
support) and (B) IVC assisted configuration (IVC support).  LPA: Left 
pulmonary artery, RPA: Right pulmonary artery SVC: Superior vena 
cava, IVC: Inferior vena cava 
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suffer from a decrease in ventricular compliance (resulting in 
ventricular diastolic dysfunction) that initiates early after the 
Fontan procedure possibly as a result of preload depletion [24].  
To simulate the failing Fontan circulation based on these 
clinical findings, we first increased the pulmonary vascular 
resistance by 68% from the baseline. Then, we reduced the 
systemic vascular resistance to compensate for the elevated 
pulmonary vascular resistance such that the total vascular 
resistance is maintained. Finally, we decreased the ventricular 
compliance from the baseline to obtain a 40% reduction in the 
cardiac output emulating ventricular diastolic dysfunction.  
D. Model of cavopulmonary support 
Using the failing Fontan LPN, we modelled the IVC and 
Fully assisted cavopulmonary support configurations as shown 
in Fig. 2.  Two thirds of the left VADs implanted in patients in 
the USA are axial-flow VADs [29], many with similar 
hydraulic characteristics curves as the Jarvik 2000 (Jarvik 
Heart, Inc., New York, NY, USA). The performance range of 
the Jarvik 2000 can encompass the characteristic curves of 
several commonly used VADs operating at their lowest rotor 
speeds  (Fig. 3A) [30], [31]. Therefore, we modelled the Jarvik 
2000 as a representative VAD in this study.   
The off-the-shelf operating range of the Jarvik pump is 8000-
12000rpm. We modified the off-the-shelf controller to achieve 
lower pump speeds down to 4400rpm, then performed a series 
of physical flow experiments to characterize the blood pump 
(Fig. 3B). The details of the flow experiments are included in 
the supplementary materials. The pump model is presented in 
the form of a quadratic equation [32], [33]. 
∆𝑃 ൌ 𝐴 𝑄ଶ ൅ 𝐵𝑄 ൅ 𝐶  (3) 
Where ∆𝑃 is the pressure head across the pump and Q is the 
flowrate through the pump ranging from 0 to 6 L.min-1. A, B, 
and C are constants dependent on the pump speed (Table. 1).  
III. RESULTS 
A. Sensitivity analysis 
We quantified the sensitivity of the Fontan hemodynamics to 
variations in the pulmonary vascular resistance and ventricular 
compliance (Fig. 4). Both example patients we simulated had a 
similar response to the sensitivity analysis. While the cardiac 
output and atrial pressure were affected by both pulmonary 
vascular resistance and ventricular compliance, they were more 
LVAD
Fig. 2. LPN model of the Fontan circulation coupled with the VAD 
describing either the (A) Full Support or (B) IVC Support scenario. 
Pressure points (Psub) are labelled on the diagram. Lsub and Rsub are 
inductor and resistor components, respectively. [22] 
  
 
 
 
 
 
TABLE 1 
Coefficients for the Jarvik 2000 blood pump performance 
characteristic model at different rotor speeds. 
Coefficients Rotor speed 
(rpm) C B A 
20.55 -0.1267 -0.002356 4400 
30.83 -0.0711 -0.003486 5500 
56.91 -0.8355 0.01323 7000 
79.86 -0.854 0.0106 8500 
107.2 -1.511 0.02024 9500 
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Fig. 3. Blood pump characteristic curves. (A) Comparison of head curves of several commonly used left VADs operating at their lowest rotor speeds vs the 
operating range of the Jarvik 2000, and (B) Performance curves of the Jarvik 2000 blood pump at different rotor speeds. 
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sensitive to the ventricular compliance. For every 25% 
decrement in the compliance, the cardiac output decreased by 
~11% and atrial pressure increased by ~24%. For every 25% 
increment in the pulmonary vascular resistance, the cardiac 
output decreased by ~3%, and atrial pressure decreased by 
<2.5%. Moreover, the slope of the lines at different levels of 
ventricular compliance indicated that the atrial pressure became 
slightly more sensitive to the pulmonary vascular resistance at 
lower ventricular compliances.   The IVC pressure is sensitive 
to changes in both the pulmonary vascular resistance and the 
ventricular compliance. 
B. Failing Fontan physiology  
In our simulations, the hemodynamic parameters of a failing 
circulation were significantly different from those of the 
healthy Fontan patients (Table. 2 and Fig. 5). Compared to the 
baseline, the arterial pressure in the failing circulation was 
significantly lower (~30%); the clinical data reported by 
Cavalcanti et al. [28] and Egbe et al. [6] similarly showed a 23% 
decrease in arterial pressure. The simulations indicated that the 
IVC pressure elevated on average by ~50% (6.5mmHg) in the 
failing Fontan patients comparing to the baseline, also 
consistent with previous reports [5], [6], [28]. The atrial 
pressure substantially increased in the failing Fontan models by 
an average of ~81 %. 
 
C. Cavopulmonary support for the failing Fontan circulation 
(Fig. 6) 
1) Fully assisted configuration 
The presence of the VAD increased the cardiac output and 
favourably decreased the IVC pressure across all pump speeds 
for the small patient but only above 5000rpm for the large 
patient. For the large patient with rpm <5000, the cardiac output 
and the IVC pressure deteriorated and changed by ~ -7.5% and 
~+5.6%, respectively. 
For both patients, the cavopulmonary VAD generally 
resulted in the reduction of the superior vena cava (SVC) 
pressure. For every 1000rpm increase in the pump speed, the 
IVC pressure decreased by ~20% and the cardiac output 
improved by ~ 10% on average. Higher pump speeds (small 
patient: >~5500rpm, large patient: >~6800rpm) led to the 
elevation of the pulmonary pressure level to >25mmHg, which 
is above safe physiological range [34]. Overall, the rpm values 
for improving cardiac output while maintaining pressures 
within safe physiological range was between 5000-6800 for the 
large patient and 4400 to 5500 rpm for the small patient. 
2) IVC assisted configuration  
While the IVC support augmented the cardiac output and led 
to a favourable decrease in the IVC pressure, the SVC pressure 
increased to above 20mmHg even at the lowest pump speed 
(4400rpm) for both patients. The IVC pressure was highly 
sensitive to the pump speed, continually decreasing with 
increasing pump speed. 
IV. DISCUSSION 
The Fontan procedure is currently the standard-of-care final 
procedure for the palliation of single ventricle defects. 
However, Fontan patients are predisposed to circulatory failure 
as a result of the abnormal hemodynamics. This study aims to 
evaluate the risks and benefits of the off-label use of a left VAD  
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TABLE 2 
Mean values of the hemodynamic parameters from simulations of the two 
example Fontan patients at baseline and during Fontan failure. 
Parameters Baseline / Failing 
 Small patient Large patient 
Height (cm) 150 180 
Weight (kg) 50 75 
BSA (m2) 1.44 1.94 
Cardiac output (L.min-1) 3.56 / 2.14 4.71 / 2.86 
Arterial pressure (mmHg) 89.44 / 63.10 87.64 / 61.69 
Atrial pressure (mmHg) 8.02 / 14.62 7.46 / 13.45 
Pulmonary pressure (mmHg) 12.29 / 18.90 11.66 / 17.88 
IVC pressure (mmHg) 12.29 / 18.90 11.66 / 17.88 
IVC: Inferior vena cava 
CO Pa Pivc Ppul Psa 
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Fig. 5. Failing Fontan hemodynamics in comparison with the baseline.  
The averaged hemodynamic data of two example failing Fontan patients 
were normalized with respect to the baseline. Cardiac output (CO), arterial 
pressure (Pa), IVC pressure (Pivc), pulmonary pressure (Ppul) and atrial 
pressure (Psa) are presented.  
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during Full and IVC support in failing Fontan patients with 
diastolic dysfunction. Through simulations, we showed that a 
proper implementation of an arterial pump in the right 
circulation could benefit the Fontan hemodynamics. We 
constructed the failing Fontan model employing clinical data 
available in the literature and found that the failing circulation 
model to be in general agreement with previous reports [16], 
[18], [35].  Our model sensitivity analysis showed the 
association of the hemodynamic parameters (e.g. cardiac 
output, IVC pressure, atrial pressure) with pulmonary vascular 
resistance and ventricular diastolic dysfunction. The results of 
this analysis suggested that the significant elevation of IVC 
pressure in a failing circulation reported in previous clinical 
studies [5], [28] is equally attributable to the high pulmonary 
vascular resistance as well as elevated downstream pressure 
related to ventricular compliance reduction. Furthermore, 
deterioration of ventricular compliance had significant 
implications on the atrial pressure, cardiac output, and central 
venous pressure; thus, it is important to include ventricular 
diastolic dysfunction in failing Fontan circulation models. The 
sensitivity analysis indicated that changes in the ventricular 
compliance and pulmonary vascular resistance had 
considerable and minimal effects on atrial pressure, 
respectively. This implies that elevated atrial pressure may be 
an indication of ventricular diastolic dysfunction in failing 
Fontan patients. The sensitivity analysis also showed that 
ventricular diastolic dysfunction and elevated pulmonary 
vascular resistance both decreased the cardiac output. Cardiac 
output reduction and consequently further preload starvation 
most likely will result in additional deterioration of the 
ventricular diastolic function [23], [36] leading to a positive 
feedback loop and eventually cardiac failure in failing Fontan 
patients. Therefore, augmentation of the cardiac output is a 
crucial factor for the survival of these patients.   
The utilization of the right-side circulatory device to promote 
the hemodynamics of a failing Fontan is appealing; however, 
implanting the cavopulmonary device on the right circulation is 
surgically complex. Implementation of the pump in a failing 
Fontan requires additional invasive surgeries for taking down 
the venae cavae for cannulation. From a surgical point of view, 
the Full assist configuration is relatively more invasive because 
of the additional steps necessary for detaching and 
anastomosing both the SVC and IVC.  
However, our simulations showed that IVC support had 
limitations. While surgical implementation of IVC assist is 
perhaps less complex, the model revealed that the pressure 
generated by the pump even at the lowest speed was  
excessively high (7mmHg at 1.66 L/min of flow) and resulted 
in elevation of the SVC and pulmonary pressure to above 
22mmHg and out of acceptable physiological ranges. Cerebral 
venous thrombosis, a result of elevated central venous pressure, 
is frequent after the Fontan operation (occurring in 21% of 
patients) [37]–[39].  Precipitous rise of the SVC pressure due to 
an IVC assist pump transmitted to the cerebral venous 
circulation could further predispose the patient to thrombosis. 
Shimazu et al. [15]  reported that IVC assist is more suitable 
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for Fontan cavopulmonary support. They modelled a similar 
size example patient with weight=75 kg and BSA=1.9 m2. The 
disparity between our conclusions is likely due to the 
differences in the pump models employed and the cardiac 
function prescribed in the physiology simulations. The pump 
model that they employed was more compatible with the low-
pressure environment. This pump, although not currently 
commercially available, was capable of generating smaller 
pressure boost at low flow rates (resulting in lower SVC 
pressure). Additionally, their example patient had a normal 
ventricular diastolic function and consequently higher IVC flow 
and cardiac output.  Nonetheless, their study also confirmed that 
the elevation of the SVC pressure by the presence of the pump 
is a major drawback of the IVC assist configuration.  
Risk of venous collapse is another important concern with 
the IVC assist configuration while using a left VAD.  Rieme et 
al. [13] observed the intermittent collapse of the IVC and 
subsequent decrease in the IVC flow in animals after 
implementing a HeartMate II in the IVC. Our simulation results 
also implied the possibility of venous collapse at the inlet of the 
pump due to the very low IVC pressure at high pump speeds.  
On the other hand, for the fully assisted configuration the caval 
pressure remained positive across all pump speeds we 
examined; this result is consistent with the report by Gandolfo 
et al. [17] where no venous collapse was observed after 
implanting the Jarvik 2000 on the right circulation of four sheep 
using the Full Support surgical configuration.  
Although the risk for venous collapse was lower in Full 
support, the simulations showed that over-filling of the Jarvik 
pump at low pump speeds was a major shortcoming of this 
configuration. In the large patient and for pump speeds 
<5000rpm, the blood pump obstructed the flow and resulted in 
a reduction of the cardiac output and undesirable increase of the 
IVC and SVC pressure. However, in the small patient no pump 
over-filling was observed due to the lower venous return flow 
rates. 
During Full support, we were able to identify a range of the 
pump speed for each example patient that resulted in improved 
hemodynamics. However, the optimal range was outside of the 
off-the-shelf range of the Jarvik 2000 (i.e. 8000-12000rpm). 
While maintaining all the pressure in the safe physiologic 
range, the cardiac output increased by up to 30% at 5500rpm 
and 6800rpm for the small and large patients, respectively. The 
optimal pump speeds depended on the specific hemodynamics 
of the failing patient and performance of the pump. Therefore, 
subject-specific modelling is important for identifying suitable 
pump speeds while investigating cavopulmonary assist. 
Limitations  
Currently, the cavopulmonary device is not employed in the 
clinical management of Fontan patients, therefore the results of 
this study cannot be validated against clinical measurements. 
Fluctuation in the rotational speed of the pump as a result of 
pulsatile flow has been observed in our previous experimental 
study [33]; while the LPN model is not capable of capturing 
these fluctuations, since the pulsatility in the pulmonary flow is 
low, these fluctuations should not result in significant error in 
the simulated hemodynamic outcomes. Another limitation of 
the current study is that the LPN model is not able to resolve 
vessel wall shear stress, which is known to impact endothelial 
function and pulmonary vascular resistance in Fontan patients.  
Finally, the numerical model is tuned based on clinical data 
from adult patients [22], therefore the results should not be 
expanded to pediatric patients. 
V. CONCLUSION 
The computational model we presented suggested that a 
cavopulmonary VAD can benefit failing Fontan patients and 
that IVC assisted configuration is associated with higher risks 
compared to Full assist. The proper adjustment of a 
cavopulmonary device depends on the device characteristics 
and hemodynamic state of the patient; we therefore recommend 
subject-specific modelling for identifying the pump speed range 
that would benefit the patient. Future studies should focus on 
designing a blood pump that has the performance requirements 
for cavopulmonary application. We showed that, theoretically, 
a modified left VAD (Jarvik 2000) implemented in the right 
circulation can help failing Fontan patients. However, further 
research is needed to examine the risks associated with the 
modification of a left VAD to achieve lower pump speeds since 
such modifications can affect the reliability and stability of the 
device. Other methods for reducing the pressure generated by 
the pump such as trimming of the rotor blades [17] can also be 
further investigated in future studies.  
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